[ad_1]
The first 5 vaccinated compatriots Italian is the option, common in many nations, to start with healthcare personnel. The first five compatriots to receive it will be the same number of Spallanzani employees in Rome: a nurse, a health social worker (OSS), a researcher and two doctors, as specified by the leadership of the Capitoline hospital.
The military will distribute the doses of the Pfizer vaccine The first doses of the Pfizer-BioNTech vaccine are scheduled for December 26, when 9,750 vials will leave Belgium and arrive at the Roman hospital. From here, so that the whole country can participate in the European Vaccine Day, the army will collect and distribute them in all other regions. Raffaele Bruno, infectious disease specialist and director of infectious diseases in San Matteo di Pavia will also be among the first to receive it.
Aifa has approved the marketing of the drug in Italy Therefore, maximum speed, but also absolute safety. The approval for the commercialization of the vaccine in Italy by Aifa, which arrived this Tuesday, is the last official step in what the president of the Italian pharmaceutical agency Giorgio Palù defines as “an exceptional day.” The Italian approval confirms the most delicate data of the vaccine that it has a very high efficacy (95% versus a required threshold of 50%) and has no contraindications insofar as it can be administered to everyone over 16 years of age in our country. country.
ALS patients can also get vaccinated “Pregnancy and breastfeeding are not contraindications and, in fact, the vaccine can be administered because the benefits can outweigh the risks,” explains Nicola Magrini, CEO of Aifa, at a press conference. “No particular precautions will be required for specific subpopulations, nor for the elderly, nor for the immunosuppressed,” he adds, specifying that patients with ALS can also be vaccinated.
One million health workers will be vaccinated in January “We will start with a limited pool of healthcare workers on Sunday and then all healthcare workers will be candidates, around a million people in the first month of January, and then the RSAs for a similar potential population volume, and subsequently the population areas identified as at risk, “Magrini emphasizes again.
Safe vaccine also in any mutation. The vaccine is also safe against any mutation of the virus, as Palù points out: “The mRna platform of the vaccine is easily modulated and allows it to be modulated in case the virus mutates to overcome the immune defenses”.
In the first few months, vaccines will be available. For the moment – the AIFA leaders specify – the campaign for the next two or three months will be managed on call (health workers and guests of the RSA with special lists of the Regions), pending the official start of the massive campaign . Meanwhile, Aifa will guarantee the pharmacological surveillance of adverse reactions, with a specific scientific committee, as well as studies of efficacy and duration of vaccination coverage. Everything is prepared, therefore, for what could be the beginning of the end of the Covid nightmare.
Monoclonal antibodies, experimentation is also evaluated in Italy A monoclonal antibody experiment against Covid-19 could also begin in Italy, already authorized as an emergency in other countries, such as the United States. This was announced by Palù during the press conference. Monoclonal antibodies, Palù recalls, “are antivirals that can be effective in already infected patients but if they are administered in the initial stages of the disease”. Already authorized by the US FDA In an emergency based on phase 2 studies, “they can be a defense until we can immunize the population” and “in the next few days we will evaluate if there is an opportunity to carry out an experiment that is able to confirm the data already produced in the scientific literature “.
Return plan for compatriots from Great Britain: residents only and emergencies After 48 hours of panic, the odyssey of Italians stranded in the United Kingdom is heading towards a happy ending, a collateral effect of the cessation of connections imposed on Sunday as a precaution against the variant of the coronavirus identified through the Canal. Now they will be able to return, at least those who reside in Italy and those who are in critical and urgent conditions. However, they will have to undergo a double swab, before and after the trip, to certify that they are negative for the virus and in any case they will have to do the scheduled 14-day quarantine once they land. Instead, excluding those permanently residing in the UK and those who only thought of visiting their families for Christmas and New Years.
English variant, G7 health: maximum international coordination On Tuesday, the meeting of the health ministers of the G7 countries was held during which the need for maximum international coordination on the evolution of the pandemic was shared, also in light of the variant of the virus that appeared in Great Britain. “Only together is it possible to face and win this challenge,” declared Health Minister Roberto Speranza, on the sidelines of the G7.
AstraZeneca: “Our vaccine is effective against the English variant” The AstraZeneca vaccine is effective against the variant of the coronavirus discovered in Great Britain. This was stated by the pharmaceutical company, indicating that studies are still being conducted to fully test the impact of the mutation. “AZD1222 contains the genetic material for the spike protein, and the changes in the genetic code seen in this new viral strain do not appear to change the structure of the spike protein,” the company says.
[ad_2]
